TD139 NEW
| Price | $64 | $129 | $213 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-15 |
Product Details
| Product Name: TD139 | CAS No.: 1450824-22-2 |
| Purity: 99.48% | Supply Ability: 10g |
| Release date: 2025/07/15 |
Product Introduction
Bioactivity
| Name | TD139 |
| Description | TD139 is a small molecule inhibitor of inhaled galectin-3 (Gal-3) with potential anti-fibrotic activity, commonly used in the study of idiopathic pulmonary fibrosis. |
| In vitro | TD139 has a high affinity for galectin-3 with a Kd of 14 nM and 10 nM for galectin-1, but low affinity for galectins 2, 4N, 4C, 7, 8N, or 9N [1]. |
| In vivo | In primary lung AECs, TD139 reduces TGF-β1–induced β-catenin translocation to the nucleus, keeping most β-catenin at the cell surface, and blocks TGF-β1–induced β-catenin phosphorylation. TD139 treatment in WT mice results in a marked reduction in lung fibrosis and β-catenin activation, along with decreased galectin-3 expression [1]. Pretreatment of WT C57BL/6 mice with TD139 attenuates liver injury, reduces infiltration of IFNγ-, IL-17-, and IL-4-producing CD4(+) T cells, increases IL-10-producing CD4(+) T cells and F4/80(+) CD206(+) alternatively activated macrophages, and prevents apoptosis of liver-infiltrating MNCs [2]. |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : Insoluble Ethanol : 3 mg/mL (4.63 mM), Sonication is recommended. DMSO : 55 mg/mL (84.79 mM), Sonication is recommended. |
| Keywords | TD-139 | TD139 | TD 139 | galectin-3 |
| Inhibitors Related | G3-C12 acetate(848301-94-0 free base) | Galectin-3 antagonist 2 | Thiodigalactoside | SNAP 398299 | Galectin-3/galectin-8-IN-1 | Galectin-3/galectin-8-IN-2 | GB1107 | DB21, Galectin-1 Antagonist | OTX008 |
| Related Compound Libraries | Nonsteroidal Anti-Inflammatory Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Fibrosis Compound Library | NO PAINS Compound Library | Clinical Compound Library | Fluorochemical Library | Anti-Metabolism Disease Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $/ |
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY